184 related articles for article (PubMed ID: 35100989)
1. Decreased serum apolipoprotein A1 level predicts poor prognosis of patients with de novo myelodysplastic syndromes.
Shi C; Gong S; Wu A; Yang S; Zou D; Zhang Y; Wu N; Ma C; Shi S; Chen Y; Wu Y; Zheng X; Huang Z; Ding J; Ouyang G; Mu Q
BMC Cancer; 2022 Jan; 22(1):127. PubMed ID: 35100989
[TBL] [Abstract][Full Text] [Related]
2. Elevated mature monocytes in bone marrow accompanied with a higher IPSS-R score predicts a poor prognosis in myelodysplastic syndromes.
Wu A; Gao P; Wu N; Shi C; Huang Z; Rong C; Sun Y; Sheng L; Ouyang G; Mu Q
BMC Cancer; 2021 May; 21(1):546. PubMed ID: 33985456
[TBL] [Abstract][Full Text] [Related]
3. Hyperfibrinogenemia as a Poor Prognostic Indicator in Myelodysplastic Syndrome.
Shi C; Gong S; Wu A; Niu T; Wu N; Zhang Y; Ouyang G; Mu Q
Cancer Manag Res; 2022; 14():1857-1865. PubMed ID: 35693118
[TBL] [Abstract][Full Text] [Related]
4. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
5. Low serum apolipoprotein A1 level predicts poor prognosis of patients with diffuse large B-cell lymphoma in the real world: a retrospective study.
Huang X; Wang Y; Huang Z; Chen X; Lin Q; Huang H; Fan L
BMC Cancer; 2024 Jan; 24(1):62. PubMed ID: 38212711
[TBL] [Abstract][Full Text] [Related]
6. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
Loeffler-Ragg J; Germing U; Sperr WR; Herrmann H; Zwierzina H; Valent P; Ulmer H; Stauder R
Crit Rev Oncol Hematol; 2011 May; 78(2):150-61. PubMed ID: 20580567
[TBL] [Abstract][Full Text] [Related]
7. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic Value of Pretherapy Peripheral Blood Inflammatory Indices in Myelodysplastic Syndromes.
Shi C; Gong S; Niu T; Li T; Wu A; Zheng X; Yang S; Ouyang G; Mu Q
Front Oncol; 2022; 12():877981. PubMed ID: 35558519
[TBL] [Abstract][Full Text] [Related]
9. Decreased transthyretin predicts a poor prognosis in primary myelodysplastic syndrome.
Chen Y; Niu T; Chen T; Wu Y; Zou D; Shi C; Wu Y; Zhang Z; Wu N; Zhang Y; Yan X; Sheng L; Lv D; Ouyang G; Chen X; Mu Q
Front Nutr; 2023; 10():1125768. PubMed ID: 36960201
[TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.
Akimoto M; Sakurai A; Nishiyama-Fujita Y; Ito C; Aisa Y; Nakazato T
Ann Hematol; 2021 Apr; 100(4):953-957. PubMed ID: 33521864
[TBL] [Abstract][Full Text] [Related]
12. PAS positivity of erythroid precursor cells is associated with a poor prognosis in newly diagnosed myelodysplastic syndrome patients.
Masuda K; Shiga S; Kawabata H; Takaori-Kondo A; Ichiyama S; Kamikubo Y
Int J Hematol; 2018 Jul; 108(1):30-38. PubMed ID: 29600427
[TBL] [Abstract][Full Text] [Related]
13. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes and characteristics of patients with
Zhang L; Chen K; Li Y; Chen Q; Shi W; Ji T; Tao H; He Z; Wang C; Yu L
Hematology; 2023 Dec; 28(1):2181773. PubMed ID: 36892252
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes.
Yan X; Wang L; Jiang L; Luo Y; Lin P; Yang W; Ren Y; Ma L; Zhou X; Mei C; Ye L; Xu G; Xu W; Yang H; Lu C; Jin J; Tong H
Cancer Med; 2021 Mar; 10(5):1759-1771. PubMed ID: 33609081
[TBL] [Abstract][Full Text] [Related]
16. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.
Loghavi S; Al-Ibraheemi A; Zuo Z; Garcia-Manero G; Yabe M; Wang SA; Kantarjian HM; Yin CC; Miranda RN; Luthra R; Medeiros LJ; Bueso-Ramos CE; Khoury JD
Br J Haematol; 2015 Oct; 171(1):91-9. PubMed ID: 26123119
[TBL] [Abstract][Full Text] [Related]
17. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores.
Reis-Alves SC; Traina F; Harada G; Campos PM; Saad ST; Metze K; Lorand-Metze I
PLoS One; 2013; 8(12):e81048. PubMed ID: 24324660
[TBL] [Abstract][Full Text] [Related]
19. Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients.
Hiwase DK; Singhal D; Strupp C; Chhetri R; Kutyna MM; Wee LA; Harrison PB; Nath SV; Wickham N; Hui CH; Gray JX; Bardy P; Ross DM; Lewis ID; Reynolds J; To LB; Germing U
Am J Hematol; 2017 Jun; 92(6):508-514. PubMed ID: 28247421
[TBL] [Abstract][Full Text] [Related]
20. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
